Tumor specific expression of survivin-2B in lung cancer as a novel target of immunotherapy
Tumor specific expression of survivin-2B in lung cancer as a novel target of immunotherapy
复制标题
DOI：
10.1016/j.lungcan.2004.10.017
复制
发表时间：
2005-05-01
期刊：
影响因子：
5.3
通讯作者：
Yasumoto, K
中科院分区：
文献类型：
--
作者：
Ichiki, Y;Hanagiri, T;Yasumoto, K
背景：Survivin-2B在多种恶性肿瘤组织中特异性表达。此外，存活素-2B包括能够结合HLA-A24的表位肽（存活素-2B（80-88））。方法：（1）采用RT-PCR方法检测15例肺癌组织和正常肺组织中Survivin-2B的表达差异。(2)进一步检测42例肺癌组织中Survivin-2B的表达，并分析其与临床病理因素的关系。(3)为了比较Survivin-2B阳性和阴性肺癌患者的前体CTL频率，用Survivin-2B（80 -88）肽刺激4例HLA-A24（+）肺癌患者的局部淋巴结淋巴细胞（LNL），其中2例肺癌患者Survivin-2B表达阳性，2例肺癌患者Survivin-2B表达阴性。Survivin-2B在肺癌组织中特异性表达，42例肺癌组织中有17例表达（42.9%）。在组织学上，它在鳞状细胞癌中的表达频率显著高于腺癌（p = 0.014）。在Survivin-2B表达（-）的肺癌患者中，LNL中前体CTL的频率约为2.0 × 10（7）分之一，而在Survivin-2B表达（+）的肺癌患者中，前体CTL的频率为5.0 × 10（6）至6.0 × 10（6）分之一。Survivin-2B在肺癌组织中特异性表达，并在肺癌患者中特异性引发细胞免疫应答，因此它可能成为肽疫苗的新候选者。(c)2004爱思唯尔爱尔兰有限公司保留所有权利。
Background: Survivin-2B is reported to be specifically expressed in numerous malignant tissues. Furthermore, survivin-2B includes the epitope peptide (survivin-2B(80-88)) which is capable of binding to HLA-A24. In this study, we evaluated whether survivin-2B could be a novel vaccine target against lung cancer.Method: (1) The differences in the survivin-2B expression between 15 sets of lung cancer tissues and normal lung tissues were investigated using RT-PCR. (2) The expression of survivin-2B was further examined in 42 lung cancer tissues, and the relationship between the expression and clinicopathologic factors was analyzed. (3) To compare the frequency of precursor CTL between survivin-2B positive and negative lung cancer patients, surivivin-2B(80-88) peptide-specific CTL were induced from regional lymph node lymphocytes (LNL) of four HLA-A24 (+) lung cancer patients, in whom two showed a positive survivin-2B expression of lung cancer while another two were negative, after stimulation with surivivin-2B(80-88).Results: Survivin-2B was specifically expressed in lung cancer tissues, and was expressed in 17 of 42 lung cancer tissues (42.9%). Histologically, it was significantly more frequently expressed in squamous cell carcinoma than in adenocarcinoma (p = 0.014). The frequency of precursor CTL in LNL was approximately one in 2.0 x 10(7) in patients with survivin-2B expression (-) lung cancer, however, it was one in 5.0 x 10(6) to 6.0 x 10(6) in those with survivin-2B expression (+) lung cancer.Conclusions: Survivin-2B was specifically expressed in lung cancer tissue, and found to specifically elicit a cellular immune response in lung cancer patients and therefore it may be a novel candidate for peptide vaccination. (c) 2004 Elsevier Ireland Ltd. All rights reserved.